Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02057445 · ClinicalTrials.gov registry record · Phase 1
3rd Party LMP1/2-Specific Cytotoxic T Lymphocytes for EBV-Associated Lymphoma
A Phase 1 study, sponsored by New York Medical College.
- Completed
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT02057445: Completed Phase 1 study, sponsored by New York Medical College.
NCT02057445 is a Phase 1 study that has completed, run by New York Medical College. The registered enrollment target is 1 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02057445, a Phase 1 study, has completed, sponsored by New York Medical College.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
The administration of allogeneic third party derived LMP specific-CTLs (special peripheral blood cells from another person) that are made specific to fight EBV infection) in Children, Adolescents and Young Adults (CAYA) with EBV-associated refractory or relapsed lymphoma will be feasible ( able to be done), safe and well tolerated (no unexpected serious events will occur). In addition, potential donors who are EBV positive will be enrolled to donate peripheral blood to help build a bank of these specific EBV fighting cell lines.
Primary Outcome
Patients will be monitored for any unexpected adverse events related to investigational product.
Interventions
- DRUG EBV CTL's
- OTHER Peripheral Blood Donor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2014-01 |
| Est. Completion | 2017-12 |
| Phase | Phase 1 |
What the finished NCT02057445 record still lists
NCT02057445 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which EBV CTL's is the first listed.
NCT02057445 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02057445 about?
NCT02057445 is a clinical study titled "3rd Party LMP1/2-Specific Cytotoxic T Lymphocytes for EBV-Associated Lymphoma". The administration of allogeneic third party derived LMP specific-CTLs (special peripheral blood cells from another person) that are made specific to fight EBV infection) in Children, Adolescents and Young Adults (CAYA) with EBV-associated refractory or relapsed lymphoma will be feasible ( able to b...
What is the current status of trial NCT02057445?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2014-01. Estimated completion is 2017-12.
What interventions are being tested in trial NCT02057445?
The interventions under investigation include: EBV CTL's (DRUG), Peripheral Blood Donor (OTHER).
Who is sponsoring clinical trial NCT02057445?
This trial is sponsored by New York Medical College, which has 47 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02057445's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia